Revenue Breakdown
Composition ()
No data
Revenue Streams
Gyre Therapeutics Inc (GYRE) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is ETUARY, accounting for 90.6% of total sales, equivalent to $27.69M. Other significant revenue streams include Etorel and Contiva. Understanding this composition is critical for investors evaluating how GYRE navigates market cycles within the Biotechnology & Medical Research industry.
Profitability & Margins
Evaluating the bottom line, Gyre Therapeutics Inc maintains a gross margin of 94.67%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 22.66%, while the net margin is 19.42%. These profitability ratios, combined with a Return on Equity (ROE) of 8.06%, provide a clear picture of how effectively GYRE converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, GYRE competes directly with industry leaders such as FULC and ATXS. With a market capitalization of $730.30M, it holds a leading position in the sector. When comparing efficiency, GYRE's gross margin of 94.67% stands against FULC's N/A and ATXS's 100.00%. Such benchmarking helps identify whether Gyre Therapeutics Inc is trading at a premium or discount relative to its financial performance.
